NCT03516188View on ClinicalTrials.gov

Efficacy of Gaviscon-Advance® in Suppressing Post-supper Acid-pocket and Night-time Acid-reflux in Obese Participants

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
Gastroesophageal Reflux DiseaseAcid RefluxObesity
Interventions
DRUG

Alginate-antacid group

Participants will be given 10 mL of alginate-antacid preparation (Gaviscon-Advance®, Reckitt-Benckiser, United Kingdom)

DRUG

Non antacid alginate group

Participants will be given 4 mL of magnesium tri-silicate which has equivalent strength and component with Gaviscon-Advance® except it is alginate-free.

Trial Locations (1)

16150

Hospitial Universiti Sains Malaysia, Kubang Kerian

All Listed Sponsors
lead

Universiti Sains Malaysia

OTHER

NCT03516188 - Efficacy of Gaviscon-Advance® in Suppressing Post-supper Acid-pocket and Night-time Acid-reflux in Obese Participants | Biotech Hunter | Biotech Hunter